BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings Guidance

Key Points

• BioMarin Pharmaceutical has updated its FY 2025 guidance, projecting an EPS of $4.400-$4.550, exceeding the consensus estimate of $3.451, and revenue of $3.1-$3.2 billion, aligning with expectations.
• On Monday, BioMarin's stock price rose to $60.31, with over 6.7 million shares traded, significantly higher than its average volume, indicating increased investor interest.
• Wall Street analysts remain optimistic, with a consensus rating of "Moderate Buy" for BioMarin shares and a price target averaging $93.74, despite some analysts adjusting their price objectives downward.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 4.400-4.550 for the period, compared to the consensus EPS estimate of 3.451. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN traded down $1.13 on Wednesday, hitting $60.80. The company's stock had a trading volume of 1,231,501 shares, compared to its average volume of 1,923,637. BioMarin Pharmaceutical has a one year low of $52.93 and a one year high of $94.85. The firm has a market capitalization of $11.66 billion, a P/E ratio of 18.05, a price-to-earnings-growth ratio of 0.83 and a beta of 0.18. The stock has a fifty day moving average of $57.24 and a two-hundred day moving average of $61.79. The company has a current ratio of 5.52, a quick ratio of 3.49 and a debt-to-equity ratio of 0.10.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several research reports. Morgan Stanley decreased their price objective on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an "overweight" rating on the stock in a report on Tuesday, July 22nd. Guggenheim upped their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday. UBS Group increased their price target on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a "buy" rating in a report on Tuesday. Wedbush reissued an "outperform" rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday. Finally, Citigroup lowered their price objective on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Six investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $94.29.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total value of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares in the company, valued at $840,600.63. The trade was a 11.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.85% of the company's stock.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. NewEdge Advisors LLC grew its stake in BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock valued at $266,000 after acquiring an additional 388 shares during the period. Focus Partners Wealth grew its position in BioMarin Pharmaceutical by 70.2% in the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company's stock valued at $835,000 after purchasing an additional 4,876 shares during the period. Finally, Empowered Funds LLC increased its stake in BioMarin Pharmaceutical by 207.4% during the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company's stock valued at $850,000 after purchasing an additional 8,112 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.